Prostate cancer (PC), the fifth leading cause of cancer-related mortality worldwide, is known
as metastatic bone cancer when it spreads to the bone. Although there is still no effective …

Abstract Treatment of castration resistant prostate cancer (CRPC) continues to represent a
major urooncological challenge due to tumor heterogeneity and the inevitable development …

Introduction Protein kinases have emerged as targetable pathways used in metastatic
prostate cancer given their role in prostatic tumor growth, proliferation and metastases …

Current clinical anti-androgen therapies in advanced prostate cancer (PCa) are driving an
increased incidence of neuroendocrine prostate cancer (NEPC), a histological variant …

Several promising targeted-therapeutics for prostate cancer (PCa), primarily affecting the
androgen receptor (AR) and the PI3K/AKT/mTOR-pathway, are in various phases of …

Prostate cancer (CaP) remains the second leading cause of cancer-related mortality in
American men. Systemic treatments for metastatic CaP, which causes the majority of deaths …

The androgen receptor (AR) signalling pathway is the key driver in most prostate cancers
(PCa), and is underpinned by several kinases both upstream and downstream of the AR …

Simple Summary Metastatic prostate cancer (mPCa) results in high mortality and there are
no effective treatments. The molecular mechanisms mediating the transition of early-stage …

Androgen deprivation therapy (ADT) is a systemic therapy for advanced prostate cancer
(PCa). Although most patients initially respond to ADT, almost all cancers eventually …

Prostate cancer remains a leading cause of death in men despite increased capacity to
diagnose at earlier stages. After prostate cancer has become hormone independent, which …